The invention belongs to the technical field of medicines, and mainly relates to application of a DOR
agonist in preparation of a
medicine for resisting
renal fibrosis. The application of the DOR
agonist is as follows: a1, a2, a3 or a4, a1, preparing a
medicine for preventing and / or treating
renal fibrosis; a2, prevention and / or treatment of
renal fibrosis; a3, activating and / or inhibiting DOR-related
cell and molecular
signal pathways; and a4, establishing an in-vitro model for activating the DOR so as to prevent and / or treat renal
fibrosis. It is found for the first time that by adopting a specific DOR
agonist (such as UFP-512) to activate DOR,
signal channels such as
Smad, p38, Akt and the like can be adjusted, and the specific DOR agonist can act on a
transcription factor Snail to regulate and control renal tubulointerstitial transformation (EMT), so that the process of renal
fibrosis is relieved. The invention expounds the relationship between the DOR and the renal
fibrosis for the first time, reveals that the DOR on the
kidney cells is activated to effectively relieve the fibrosis
lesion of the
kidney cells, provides a new way for preventing and treating the
pathological change of the renal fibrosis, and has important scientific value and
clinical significance.